SwePub
Sök i LIBRIS databas

  Utökad sökning

L773:1567 567X OR L773:1573 8744
 

Sökning: L773:1567 567X OR L773:1573 8744 > Challenges of a mec...

Challenges of a mechanistic feedback model describing nicotinic acid-induced changes in non-esterified fatty acids in rats

Gabrielsson, Johan (författare)
Swedish University of Agricultural Sciences,Sveriges lantbruksuniversitet,Inst för biomedicin och veterinär folkhälsovetenskap,Department of Biomedical Science and Veterinary Public Health
 (creator_code:org_t)
 
2013-07-04
2013
Engelska.
Ingår i: Journal of Pharmacokinetics and Pharmacodynamics. - : Springer Science and Business Media LLC. - 1567-567X .- 1573-8744. ; 40, s. 497-512
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Previously, we developed a feedback model to describe the tolerance and oscillatory rebound of non-esterified fatty acid (NEFA) plasma concentrations in male Sprague Dawley rats after intravenous infusions of nicotinic acid (NiAc). This study challenges that model, using the following regimens of intravenous and oral NiAc dosing in male Sprague Dawley rats (n = 95) to create different patterns of exposure: (A) 30 min infusion at 0, 1, 5 or 20 mu mol kg(-1) body weight; (B) 300 min infusion at 0, 5, 10 or 51 mu mol kg(-1); (C) 30 min infusion at 5 mu mol kg(-1), followed by a stepwise decrease in rate every 10 min for 180 min; (D) 30 min infusion at 5 mu mol kg(-1), followed by a stepwise decrease in rate every 10 min for 180 min and another 30 min infusion at 5 mu mol kg(-1) from 210 to 240 min; (E) an oral dose of 0, 24.4, 81.2 or 812 mu mol kg(-1). Serial arterial blood samples were taken for measurement of plasma NiAc and NEFA concentrations. The gradual decrease in infusion rate in (C) and (D) were also designed to test the hypothesis that a gradual reduction in NiAc plasma concentration may be expected to reduce or prevent rebound. The absorption of NiAc was described by parallel linear and non-linear processes and the disposition of NiAc by a two-compartment model with endogenous turnover rate and two parallel capacity-limited elimination processes. NEFA (R) turnover, which was driven by the plasma concentration of NiAc via an inhibitory drug-mechanism function acting on NEFA formation, was described by a feedback model with a moderator distributed over a series of transit compartments, where the first compartment (M (1)) inhibited the formation of R and the last compartment (M (N) ) stimulated the loss of R. All processes regulating the plasma NEFA concentration were assumed to be captured by the moderator function. Data were analyzed using non-linear mixed effects modeling (NONMEM). The potency IC (50) of NiAc was 68 nmol L-1, the fractional turnover rate k (out) 0.27 L mmol(-1) min(-1), and the turnover rate of moderator k (tol) 0.023 min(-1). The lower physiological limit of NEFA, which was modeled as a NiAc-independent release (k (cap) ) of NEFA into plasma, was estimated to 0.023 mmol L-1 min(-1). The parameter estimates derived in this study were consistent with our previous estimates, suggesting that the model may be used for prediction of the NEFA response time-course following different modes and routes administration of NiAc or NiAc analogues. In order to avoid NiAc-induced NEFA rebound, a slow decline in the NiAc exposure pattern is needed at or below IC (50).

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...
Gabrielsson, Joh ...
Om ämnet
MEDICIN OCH HÄLSOVETENSKAP
MEDICIN OCH HÄLS ...
och Medicinska och f ...
och Farmakologi och ...
Artiklar i publikationen
Journal of Pharm ...
Av lärosätet
Sveriges Lantbruksuniversitet

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy